Northland Capmk Expects Increased Earnings for MiMedx Group

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Analysts at Northland Capmk lifted their FY2024 EPS estimates for MiMedx Group in a research note issued to investors on Thursday, October 31st. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.28 for the year, up from their previous forecast of $0.23. The consensus estimate for MiMedx Group's current full-year earnings is $0.26 per share. Northland Capmk also issued estimates for MiMedx Group's Q4 2024 earnings at $0.07 EPS.

A number of other analysts have also commented on the stock. Craig Hallum reduced their price target on shares of MiMedx Group from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Cantor Fitzgerald restated an "overweight" rating and set a $11.00 target price on shares of MiMedx Group in a research note on Thursday, August 1st. Finally, StockNews.com raised MiMedx Group from a "buy" rating to a "strong-buy" rating in a report on Thursday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, MiMedx Group has an average rating of "Buy" and an average price target of $12.00.

MiMedx Group Stock Up 2.9 %

MDXG stock traded up $0.20 during midday trading on Monday, hitting $7.13. The company's stock had a trading volume of 1,327,699 shares, compared to its average volume of 713,482. The company has a market cap of $1.05 billion, a PE ratio of 12.96 and a beta of 1.94. The firm's 50-day moving average is $6.07 and its 200-day moving average is $6.68. MiMedx Group has a 12 month low of $5.47 and a 12 month high of $9.27. The company has a current ratio of 4.10, a quick ratio of 3.22 and a debt-to-equity ratio of 0.10.

Institutional Investors Weigh In On MiMedx Group

Several large investors have recently bought and sold shares of the business. Caxton Associates LP purchased a new stake in MiMedx Group in the 1st quarter worth about $1,018,000. Victory Capital Management Inc. raised its stake in MiMedx Group by 909.0% in the second quarter. Victory Capital Management Inc. now owns 138,449 shares of the company's stock valued at $959,000 after buying an additional 124,727 shares during the last quarter. Isthmus Partners LLC raised its position in shares of MiMedx Group by 30.4% in the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company's stock valued at $27,000 after purchasing an additional 91,714 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of MiMedx Group by 13.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company's stock worth $254,000 after buying an additional 3,806 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in MiMedx Group by 47.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company's stock worth $8,958,000 after acquiring an additional 413,443 shares during the period. Institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.